Evidence map›Paper›PMID 41559523›Full record

ArticleFEBS open bio2026

RETRACTION: The PI3K/mTOR Dual Inhibitor NVP-BEZ235 Stimulates Mutant p53 Degradation to Exert Anti-Tumor Effects on Triple-Negative Breast Cancer Cells.

Abstract readRetraction Notice
In one paragraph

Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

retractionJ. Cai, J. Xia, J. Zou, Q. Wang, Q. Ma, R. Sun, H. Liao, L. Xu, D. Wang, and X. Guo, "The PI3K/mTOR Dual Inhibitor NVP-BEZ235 Stimulates Mutant p53 Degradation to Exert Anti-Tumor Effects on Triple-Negative Breast Cancer Cells," FEBS Open Bio 10, no. 4 (2020): 535-545, https://doi.org/10.1002/2211-5463.12806. The above article, published online on 06 February 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Miguel De la Rosa; the Federation of European Biochemical Societies; and John Wiley & Sons Ltd. The retraction has been agreed upon following an investigation into concerns raised by a third party. The investigation found multiple duplications of western blot bands among Figures 2A, 2B, 3A, 4A, 4B, 4C, 5A, and 5C. An overlap was also detected between the MDA-MB-468 0h CON image and the MDA-MB-468 0 h BEZ235 image shown in Figure 1B. The authors did not respond to address the concerns raised. Given the extent of the identified issues, the editors have lost confidence in the data presented and consider the conclusions of this manuscript substantially compromised. As a result, the Editor-in-Chief, FEBS Press, and John Wiley and Sons Ltd. have determined that a retraction is necessary. The authors were informed of the decision to retract but did not respond to requests for comment.

Identifiers

PMID41559523
PMCPMC12955744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.